Magnetic paclitaxel nanoparticles inhibit glioma growth and improve the survival of rats bearing glioma xenografts

Anticancer Research

Volumn 30, Issue 6, 2010, Pages 2217-2223

  Zhao, Ming ^a   Liang, Chao ^a   Li, Anmin ^a   Chang, Jin ^b   Wang, Hanjie ^b   Yan, Runmin ^a   Zhang, Jiajing ^a   Tai, Junli ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b TIANJIN UNIVERSITY   (China)

Author keywords

Glioma; Magnetic nanoparticles; Magnetic targeting; Paclitaxel; Rats

Indexed keywords

PACLITAXEL; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG RELEASE; GLIOMA; GLIOMA CELL; IN VITRO STUDY; IN VIVO STUDY; MAGNETISM; NANOFABRICATION; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR MODEL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRAIN NEOPLASMS; CELL LINE, TUMOR; CEREBRAL CORTEX; GLIOMA; HUMANS; MAGNETICS; NANOPARTICLES; PACLITAXEL; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77955072673     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Wen PY and Kesari S: Malignant gliomas in adults. N Engl J Med 359: 492-507, 2008.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E and Mirimanoff RO: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
3. Hochberg FH and Pruitt A: Assumptions in the radiotherapy of glioblastoma. Neurology 30: 907-911, 1980.
4. Schiff PB, Fant J and Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature 277: 665-667, 1979.
5. Liebmann JE, Cook JA, Lipschultz C, Teague D, Fisher J and Mitchell JB: Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. Br J Cancer 68: 1104-1109, 1993. (Pubitemid 23356660)
6. Sanson M, Napolitano M, Yaya R, Keime-Guibert F, Broët P, Hoang-Xuan K and Delattre JY: Second-line chemotherapy with docetaxel in patients with recurrent malignant glioma: a phase II study. J Neurooncol 50: 245-249, 2000.
7. Glantz MJ, Choy H, Kearns CM, Mills PC, Wahlberg LU, Zuhowski EG, Calabresi P and Egorin MJ: Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors. J Natl Cancer Inst 87: 1077-1081, 1995.
8. Gurney JG and Kadan-Lottick N: Brain and other central nervous system tumors: rates, trends, and epidemiology. Curr Opin Oncol 13: 160-166, 2001.
9. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhänel M, Spruss T, Bernhardt G, Graeff C, Färber L, Gschaidmeier H, Buschauer A and Fricker G: Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 110: 1309-1318, 2002.
10. Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM and Brem H: Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf 6: 609-621, 2007.
11. Walter KA, Cahan MA, Gur A, Tyler B, Hilton J, Colvin OM, Burger PC, Domb A and Brem H: Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma. Cancer Res 54: 2207-2212, 1994.
12. McBain SC, Yiu HH and Dobson J: Magnetic nanoparticles for gene and drag delivery. Int J Nanomedicine 3: 169-180, 2008. (Pubitemid 352037850)
13. Sakamoto J, Annapragada A, Decuzzi P and Ferrari M: Antibiological barrier nanovector technology for cancer applications. Expert Opin Drug Deliv 4: 359-369, 2007.
14. Liang XF, Wang HJ, Luo H, Tian H, Zhang BB, Hao LJ, Teng JI and Chang J: Characterization of novel multifunctional cationic polymeric liposomes formed from octadecyl quaternized carboxymethyl chitosan/cholesterol and drug encapsulation. Langmuir 24: 7147-7153, 2008.
15. Laquintana V, Trapani A, Denora N, Wang F, Gallo JM and Trapani G: New strategies to deliver anticancer drugs to brain tumors. Expert Opin Drug Deliv 6: 1017-1032, 2009.
16. Lin SH and Kleinberg LR: Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies. Expert Rev Anticancer Ther 8: 343-359, 2008.
17. Clarke JL, Iwamoto FM, Sul J, Panageas K, Lassman AB, DeAngelis LM, Hormigo A, Nolan CP, Gavrilovic I, Karimi S and Abrey LE: Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol 27: 3861-3867, 2009.
18. Puffer SK, Ciccotto SL and Gallo JM: Distribution of small magnetic particles in brain tumor-bearing rats. J Neurooncol 47: 99-105, 1999.
19. Alexiou C, Jurgons R, Seliger C, Branke O, Iro H and Odenbach S: Delivery of superparamagnetic nanoparticles for local chemotherapy after intraarterial infusion and magnetic drug targeting. Anticancer Res 27: 2019-2022, 2007.
20. Schroder U and Sabel BA: Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections. Brain Res 710: 121-124, 1996.
21. Hillaireau H and Couvreur P: Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci 66: 2873-2896, 2009.
22. Lenaerts V, Couvreur P, Christiaens-Leyh D, Joiris E, Roland M, Rollman B and Speiser P: Degradation of poly (isobutyl cyanoacrylate) nanoparticles. Biomaterials 5: 65-68, 1984. (Pubitemid 14169302)
23. Roiter Y, Ornatska M, Rammohan AR, Balakrishnan J, Heine DR and Minko S: Interaction of lipid membrane with nanostructured surfaces. Langmuir 25: 6287-6299, 2009.
24. Park J and Lu W: Interaction of nanoparticles with lipid layers. Phys Rev E Stat Nonlin Soft Matter Phys 80: 021607, 2009.
25. Chertok B, David AE, Huang Y and Yang VC: Glioma selectivity of magnetically targeted nanoparticles: a role of abnormal tumor hydrodynamics. J Control Release 122: 315-323, 2007.
26. Sarin H, Kanevsky AS, Wu H, Brimacombe KR, Fung SH, Sousa AA, Auh S, Wilson CM, Sharma K, Aronova MA, Leapman RD, Griffiths GL and Hall MD: Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells. J Transl Med 6: 80, 2008.
27. Douglas KL, Piccirillo CA and Tabrizian M: Cell line-dependent internalization pathways and intracellular trafficking determine transfection efficiency of nanoparticle vectors. Eur J Pharm Biopharm 68: 676-687, 2008.